Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$16.30
+0.8%
$15.88
$13.09
$18.92
$5.82B0.56424,861 shs44,179 shs
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$31.07
+1.6%
$30.28
$28.56
$38.79
$13.13B0.561.13 million shs257,310 shs
Solventum Corporation stock logo
SOLV
Solventum
$80.00
+2.6%
$77.47
$62.38
$88.20
$13.85B0.661.40 million shs107,390 shs
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$93.03
+1.8%
$87.90
$79.12
$108.29
$18.00B0.462.27 million shs102,878 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%-0.12%-0.33%+2.20%+13.96%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.00%-0.29%+1.75%-4.92%-3.57%
Solventum Corporation stock logo
SOLV
Solventum
0.00%-4.11%-1.94%+11.67%+4.31%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.00%+0.19%-1.69%-1.32%-6.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$16.30
+0.8%
$15.88
$13.09
$18.92
$5.82B0.56424,861 shs44,179 shs
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$31.07
+1.6%
$30.28
$28.56
$38.79
$13.13B0.561.13 million shs257,310 shs
Solventum Corporation stock logo
SOLV
Solventum
$80.00
+2.6%
$77.47
$62.38
$88.20
$13.85B0.661.40 million shs107,390 shs
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$93.03
+1.8%
$87.90
$79.12
$108.29
$18.00B0.462.27 million shs102,878 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%-0.12%-0.33%+2.20%+13.96%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.00%-0.29%+1.75%-4.92%-3.57%
Solventum Corporation stock logo
SOLV
Solventum
0.00%-4.11%-1.94%+11.67%+4.31%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.00%+0.19%-1.69%-1.32%-6.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.21
Hold$18.0010.84% Upside
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
2.17
Hold$30.931.28% Upside
Solventum Corporation stock logo
SOLV
Solventum
2.38
Hold$81.914.99% Upside
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
2.21
Hold$100.7010.24% Upside

Current Analyst Ratings Breakdown

Latest BLCO, ZBH, SOLV, and SNN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
UpgradeSell (E+)Sell (D-)
7/20/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
DowngradeHold (C-)Sell (D+)
7/17/2026
Solventum Corporation stock logo
SOLV
Solventum
UpgradeHold (C)Hold (C+)
7/13/2026
Solventum Corporation stock logo
SOLV
Solventum
Reiterated RatingBuy$91.00
7/9/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
DowngradeSell (D-)Sell (E+)
7/8/2026
Solventum Corporation stock logo
SOLV
Solventum
Initiated CoverageMarket Perform$81.00
7/8/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Initiated CoverageOutperformMarket Perform$95.00
7/8/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Boost Price TargetBuy$19.00 ➝ $21.00
7/8/2026
Solventum Corporation stock logo
SOLV
Solventum
UpgradeHold
7/8/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
UpgradeHold
7/6/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Reiterated RatingHold (C-)
(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$5.10B1.14$1.68 per share9.69$18.40 per share0.88
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$6.16B2.09$3.43 per share8.91$12.45 per share2.45
Solventum Corporation stock logo
SOLV
Solventum
$8.33B1.62$8.99 per share8.68$29.11 per share2.68
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$8.41B2.10$13.74 per share6.65$64.11 per share1.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$360M-$0.62N/A15.180.50-4.21%3.60%1.69%7/29/2026 (Estimated)
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$625MN/AN/A12.311.11N/AN/AN/A8/4/2026 (Estimated)
Solventum Corporation stock logo
SOLV
Solventum
$1.56B$8.169.5610.991.2017.33%23.51%7.63%8/5/2026 (Estimated)
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$705.20M$3.8523.7310.242.699.05%13.24%7.28%8/5/2026 (Estimated)

Latest BLCO, ZBH, SOLV, and SNN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Solventum Corporation stock logo
SOLV
Solventum
$1.91N/AN/AN/A$2.15 billionN/A
8/5/2026Q2 2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$2.01N/AN/AN/A$2.14 billionN/A
8/4/2026Q2 2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.94N/AN/AN/A$1.64 billionN/A
7/29/2026Q2 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.16N/AN/AN/A$1.37 billionN/A
5/5/2026Q1 2026
Solventum Corporation stock logo
SOLV
Solventum
$1.35$1.48+$0.13$0.07$1.97 billion$2.01 billion
4/29/2026Q1 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion
4/28/2026Q1 2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$1.86$2.09+$0.23$1.22$2.07 billion$2.09 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.933.05%N/AN/AN/A
Solventum Corporation stock logo
SOLV
Solventum
N/AN/AN/AN/AN/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$0.961.05%N/A24.94%N/A

Latest BLCO, ZBH, SOLV, and SNN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/22/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
quarterly$0.241.06%6/25/20266/25/20267/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.78
1.53
0.99
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.60
2.57
1.25
Solventum Corporation stock logo
SOLV
Solventum
0.96
1.07
0.75
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.50
1.73
0.95

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
25.64%
Solventum Corporation stock logo
SOLV
Solventum
N/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
88.89%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.45%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.00%
Solventum Corporation stock logo
SOLV
Solventum
0.24%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
1.28%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,000357.06 million351.88 millionOptionable
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
16,988422.52 million418.29 millionOptionable
Solventum Corporation stock logo
SOLV
Solventum
20,000173.18 million172.76 millionOptionable
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
17,000193.46 million190.99 millionOptionable

Recent News About These Companies

Zimmer Biomet (NYSE:ZBH) Upgraded by Wall Street Zen to "Buy" Rating

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$16.30 +0.13 (+0.80%)
As of 10:15 AM Eastern

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Smith & Nephew SNATS stock logo

Smith & Nephew SNATS NYSE:SNN

$31.07 +0.50 (+1.64%)
As of 10:16 AM Eastern

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Solventum stock logo

Solventum NYSE:SOLV

$80.00 +1.99 (+2.55%)
As of 10:16 AM Eastern

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

Zimmer Biomet stock logo

Zimmer Biomet NYSE:ZBH

$93.03 +1.68 (+1.84%)
As of 10:16 AM Eastern

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.